Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.
– Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA, a Switzerland based speciality pharma company, today announced a collaboration to pursue the development of Almac Discovery’s Wee-1 kinase inhibitor programme.
Almac Group’s Diagnostics business unit announced today it was granted intellectual property protection for its DNA Damage Response Deficiency (DDRD) assay.
Inhibitors of Wee-1 kinase, cell cycle regulator, have potential for clinical utility across a broad range of cancer indications
Almac Group’s Diagnostics business unit today announced the Journal of European Urology has published results relating to its Prostate Cancer Metastatic Assay. The publication demonstrates the assay can be used to analyse primary prostate cancer FFPE samples to identify a molecular subgroup with a high risk of developing distant metastases. The assay therefore has the potential to guide the choice of therapy for patients presenting with primary prostate cancer.
Craigavon based global contract pharmaceutical development and manufacturing organisation, Almac Group, has secured new premises in Dundalk, County Louth to support its ongoing global expansion plans in response to increased client demand.
Partnership to support the discovery and development of novel biomarkers, enabling personalised medicine
Sri Krishna Pharmaceuticals greatly increase production of APIs with Russell Finex screening solutions
Oncopeptides AB recently announced that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma.
Products, quality is often defined by a range of functional and sensory attributes, some of which may be easily measured - such as color - and others which may not. Visual or textural appearance and ease of application exemplify properties in this second category. Ultimately these attributes are assessed subjectively via user feedback, but relying on such information to guide formulation is somewhat impractical, particularly in the early stages of product development. Metrics that reliably correlate with product performance are therefore essential.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.